Abstract
Patients with axSpA are likely to live with a range of hopes, such as retaining a good quality of life and normal social and physical functioning, and fears, including a fear of suffering, losing autonomy, and being a burden on relatives, relating to their disease (Garrido-Cumbrera et al. Rheumatol Ther. 2017:219–231, 2017; Gossec et al. Value Health. 18:A715, 2015).
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
Patients with axSpA are likely to live with a range of hopes, such as retaining a good quality of life and normal social and physical functioning, and fears, including a fear of suffering, losing autonomy, and being a burden on relatives, relating to their disease (Garrido-Cumbrera et al. 2017; Gossec et al. 2015). Addressing these needs is an important consideration when designing appropriate treatment strategies for axSpA, particularly in light of the latest treatment recommendations, which advocate a shared decision-making process between patients and clinicians, including co-defining treatment goals (Heijde et al. 2017; Smolen et al. 2018).
12.1 Fears Reported by European IMAS Participants
The most frequently reported fears among survey participants were disease progression (32.9%), suffering pain (30.5%), loss of mobility (30.0%), and loss of independence/disability (29.2%) (Fig. 12.1). These findings are similar to those reported in another qualitative study in France which found that patients with axSpA most commonly feared suffering loss of autonomy and mobility and becoming a burden for relatives (Gossec et al. 2015).
Accordingly, the two most frequently reported hopes, halting disease progression (32.5%) and eliminating pain (30.7%), mirrored the most common fears (Fig. 12.2). Participants also expressed their hopes to obtain effective treatment (23.3%) and improve quality of life (22.0%). These findings are broadly in agreement with those reported in previous studies (Kiltz et al. 2016; Berenbaum et al. 2014), although it is notable that certain hopes reported previously, such as improving sleep quality, reducing fatigue, and improving motivation, were not frequently reported in the IMAS European survey (Kiltz et al. 2016; Berenbaum et al. 2014). The reason for this discrepancy is unclear but may be due to differences in study design, specifically the use of free text responses versus established multiple choice categories.
The core set of fears and hopes reported in the IMAS survey and previous studies may reflect unmet needs and key gaps in the information given to patients about their disease, its outlook, and its management. Optimal axSpA management should incorporate education for patients to minimize misconceptions, clarify treatment expectations, ensure patients feel supported, and ultimately improve health outcomes. As several factors, including the patient–physician relationship and treatment adherence, may affect axSpA-related hopes and fears (Gossec et al. 2018), it is critical for patients to share their thoughts with their physician to ensure the best possible management of their disease.
12.2 Treatment Goals for Patients with axSpA
The treatment goals most commonly reported by the European IMAS survey participants were to eliminate or reduce pain (28.6%) and improve mobility (19.3%; Fig. 12.3). Improved management of pain has previously been highlighted as a key treatment priority of patients with axSpA (Kiltz et al. 2016; Berenbaum et al. 2014). Given that improved mobility (a treatment goal for nearly one in five patients) correlates with improved quality of life (Huang et al. 2017), it is interesting that the proportion of participants who stated that improving quality of life was a treatment goal was relatively low. This may reflect variation between participants in their interpretation of the term ‘quality of life’.
Some of the treatment goals reported by participants were inconsistent with their hopes and fears. There are several possible explanations for this. For example, some participants may not have considered their hopes as being realistic treatment goals; this highlights the importance of patient–clinician discussions of fears, hopes, and treatment goals in order to improve education and facilitate shared decision making (Heijde et al. 2017). Accordingly, participants may also have reported their treatment goals as being those suggested by their clinician rather than what they personally believed. The results may also have been affected by ‘respondent fatigue’, a term used to describe a situation where survey respondents become ‘tired’ of answering questions, particularly when they appear to be asking the same thing several times; some participants may therefore have reported something as a treatment goal then not thought it necessary to state it again when reporting fears or hopes later in the survey. Finally, the use of open versus closed questions in the study design allowed discrepancies such as these to arise.
12.3 Patient–Clinician Communication is Important for Optimal Disease Management
As indicated in the ASAS-EULAR recommendations for axSpA management, shared decision-making requires patients to be educated about their disease and treatment options to enable a collaborative approach to defining an appropriate treatment goal (Heijde et al. 2017; Smolen et al. 2018). However, more than one-third of IMAS participants (36.8%) had not talked with their managing physician about their personal treatment goals (Fig. 12.4). This represents a key area where improvement is required.
The hopes and fears reported by European IMAS participants were generally aligned with medical priorities and guidelines highlighting the importance of maximizing health-related quality of life (Heijde et al. 2017). Current guidelines recommend that axSpA treatment should be individualized according to the current signs and symptoms along with characteristics such as comorbidities and psychosocial factors (Heijde et al. 2017). As many of these factors are only known to the patient, improvements in patient–clinician discussions may allow the clinician to offer the most appropriate education/advice and potentially treatment adjustment. Clinicians also need to be encouraged to be transparent with patients and acknowledge areas of uncertainty within axSpA management due to lack of evidence.
12.4 Conclusions
-
Survey participants’ most common disease-related fears were disease progression, suffering pain, and loss of mobility. Nevertheless, they hoped to halt disease progression, eliminate pain, obtain effective treatments, and improve quality of life.
-
These insights into what is relevant for patients may reflect unmet treatment needs and key gaps in the information given about their disease, its outlook, and its management that could be addressed through improved education.
-
One out of three participants reported that they had not talked to their clinician about their personal treatment goals.
-
Patients with axSpA may achieve better health outcomes through adjusting therapy with an aim of achieving a specific treatment goal (Smolen et al. 2018); proactive and transparent discussions of expectations and treatment goals between HCPs and patients should be encouraged to enable effective shared-decision making and the design of individualized treatment strategies that provide optimal management of the disease.
References
Berenbaum F, Chauvin P, Hudry C, et al. Fears and beliefs in rheumatoid arthritis and spondyloarthritis: a qualitative study. PLoS One. 2014;9:e114350.
Garrido-Cumbrera M, Hillmann O, Mahapatra R, et al. Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients. Rheumatol Ther. 2017;2017(4):219–31.
Gossec L, Chauvin P, Hudry C, et al. The most frequent fears and beliefs of 226 patients with rheumatoid arthritis or spondyloarthritis, using a novel questionnaire. Value Health. 2015;18:A715.
Gossec L, Chauvin P, Saraux A, et al. Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. Ann Rheum Dis. 2018;77:258–63.
Huang JC, Qian BP, Qiu Y, et al. Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: a retrospective case series study. BMC Musculoskelet Disord. 2017;18:352.
Kiltz U, Essers I, Hiligsmann M, et al. Which aspects of health are most important for patients with spondyloarthritis? a best worst scaling based on the ASAS health index. Rheumatology (oxford). 2016;55:1771–6.
Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3–17.
van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–91.
Author information
Authors and Affiliations
Consortia
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2022 The Author(s)
About this chapter
Cite this chapter
Garrido-Cumbrera, M. et al. (2022). Fears and Hopes. In: Axial Spondyloarthritis: Patient-Reported Impact in Europe. Springer, Cham. https://doi.org/10.1007/978-3-030-97606-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-97606-4_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-97605-7
Online ISBN: 978-3-030-97606-4
eBook Packages: MedicineMedicine (R0)